Literature DB >> 25827172

Chronic fatigue is prevalent and associated with hormonal dysfunction in long-term non-Hodgkin lymphoma survivors treated with radiotherapy to the head and neck region.

Mette Seland1, Harald Holte2, Trine Bjøro3,4, Thomas Schreiner5, Jens Bollerslev3,5, Jon Håvard Loge1,6, Sophie D Fosså1, Cecilie E Kiserud1.   

Abstract

The purposes of this study were to assess the prevalence of chronic fatigue (CF) in irradiated survivors of non-Hodgkin lymphoma, analyze for associations between hormonal dysfunction and CF, and to investigate the associations between CF and functioning. Invited survivors were all treated with radiation to the head and neck region, with or without additional chemotherapy. The participants (n=98) responded to questionnaires measuring CF, mental distress (HADS), and functioning (SF-36), and had blood drawn for analyses of four hormonal axes. Hormonal status was categorized as normal, hormone dysfunction in one or more axes, or hormone replacement therapy. A total of 29% of the survivors had CF. In multivariate analyses there was an increased risk of CF among survivors with untreated hormone dysfunction (OR 3.87, 95% CI: 1.20-12.51, p=0.02). Survivors on hormone substitution did not have increased risk for CF compared to survivors with normal hormonal status. CF was significantly associated with reduced functioning.

Entities:  

Keywords:  Fatigue; Hormonal dysfunction; Non-Hodgkin lymphoma survivors

Mesh:

Substances:

Year:  2015        PMID: 25827172     DOI: 10.3109/10428194.2015.1036258

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue.

Authors:  Alexander Fosså; Knut Halvor Smeland; Øystein Fluge; Karl Johan Tronstad; Jon Håvard Loge; Øivind Midttun; Per Magne Ueland; Cecilie Essholt Kiserud
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.